T
Terns Pharmaceuticals, Inc. (TERN)
NMS – Real Time Price. Currency in USD
52.95
+52.95 (0.00%)
At close: May 4, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
52.95
+52.95 (0.00%)
At close: May 4, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 62.41 | 6.05 | 10 | |
| Quick ratio | 62.41 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -1M | -881K | -896K | -501K | -501K |
| Operating Income | -62M | -103M | -102M | -110M | -110M |
| Net Income | -60M | -90M | -89M | -96M | -96M |
| EBITDA | -61M | -102M | -101M | -110M | -110M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -0.48 | 1.0 |
| Next quarter | N/A | -2.88 | 1.0 |
| Current year | N/A | -9.59 | 1.0 |
| Next year | N/A | -22.39 | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 4.32 | 9.26 | 3.49 | 6.0 |
| Y/Y | 999 | -8.12 | -2.07 | -28.09 | 3.3 |
| 3y average | 999 | -18.74 | 14.6 | -18.89 | 5.0 |
| 5y average | 779.2 | -29.47 | 17.06 | -22.24 | 5.3 |
| Weighted average score | 4.9 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $524.7M significantly exceed its total debt $919.0K, ensuring strong financial flexibility
Total current assets $1.0B exceed Total current liabilities $16.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$19.1M limits the company's ability to reinvest or pay down debt